Perspectives

Nature Reviews Microbiology 1, 237-242 (December 2003) | doi:10.1038/nrmicro777

InnovationClostridia in cancer therapy

Nigel P. Minton1  About the author

Top

During the past decade, the search for an effective system for the selective delivery of high therapeutic doses of anti-cancer agents to tumours has explored a variety of ingenious and increasingly complex biological systems. These systems are most often based on gene therapy and use viral vectors as the delivery vehicle. Invariably, such systems have been found wanting with respect to a lack of tumour specificity, poor levels of transgene expression and inefficient distribution of the vector throughout the tumour mass. By contrast, the ability of intravenously injected clostridial spores to infiltrate, then selectively germinate in, the hypoxic regions of solid tumours seems to be a totally natural phenomenon, which requires no fundamental alterations and is exquisitely specific.

Author affiliations

  1. Nigel P. Minton is at the Institute of Infections, Immunity and Inflammation and the School of Pharmacy, University of Nottingham, Floor C, West Block, Queens Medical Centre, Nottingham NG7 2UH, UK.
    Email: nigel.minton@nottingham.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated

RESEARCH
Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N
Cancer Gene Therapy Original Article (18 Dec 2002)
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients
Cancer Gene Therapy Original Article (01 Oct 2003)
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
Cancer Gene Therapy Original Article (17 May 2001)

Extra navigation

Subscribe

Subscribe to Nature Reviews Microbiology

Search PubMed for

Open Innovation Challenges

Advertisement